Overview

Study to Evaluate the Pharmacokinetics (PK) of E7090 and Its Metabolite in Participants With Mild and Moderate Hepatic Impairment Compared to Healthy Participants

Status:
Recruiting
Trial end date:
2022-05-31
Target enrollment:
Participant gender:
Summary
The primary purpose of the study is to evaluate the effects of mild and moderate hepatic impairment on PK of E7090 after a single dose administration.
Phase:
Phase 1
Details
Lead Sponsor:
Eisai Inc.